期刊文献+

CpG ODN B对鸡新城疫重组杆状病毒疫苗的免疫增强效应 被引量:3

Immune Enhancement of CpG ODN B on Recombinant Baculovirus Vaccine Against Newcastle Disease in Chickens
下载PDF
导出
摘要 目的:探究CpG ODN作为疫苗佐剂对鸡新城疫重组杆状病毒疫苗的免疫效果。方法:将CpG ODN B/P这2种类型的免疫佐剂分别与鸡新城疫重组杆状病毒载体疫苗BV-BXY-F混合后,以鼻腔免疫方式进行鸡体免疫,并进行攻毒保护实验,通过对鸡体的临床症状观察,以及检测免疫保护率、中和抗体水平、淋巴细胞增殖活性、细胞因子含量,分析各CpG ODN对鸡新城疫疫苗免疫效果的影响。结果:BV-BXY-F+CpG ODN B免疫组鸡在免疫后42 d中和抗体效价最高,免疫保护率100%,中和抗体效价,sIgA、IgG、IgA、IFN-γ、IL-2、IL-4、CD4^+T细胞、CD8^+T细胞含量较BV-BXY-F+CpG ODN P组分别提高了32.08%、8.44%、13.56%、23.71%、50.20%、132.97%、39.76%、38.43%、25.99%,且差异显著(P<0.05),与单独免疫组BV-BXY-F相比分别提高了13.71%、89.39%、10.41%、21.26%、159.17%、52.71%、237.84%、80.51%、75.57%。结论:CpG ODN B对增强鸡新城疫重组杆状病毒疫苗的免疫增强效果最好。 Objective:To explore the immune enhancement of CpG ODN B as a vaccine adjuvant on recombinant baculovirus vaccine against Newcastle disease in chickens.Methods:Two types of CpG ODN B/P were used as immune adjuvants and the recombinant baculovirus vector vaccine BV-BXY-F was mixed,and the nasal immunization method and the challenge protection experiment were carried out in chickens.The immune improvement effect CpG ODN in the recombinant baculovirus vector vaccine BV-BXY-F was evaluated by detection of clinical symptoms,immune protection rate,the neutralizing antibody level,protection efficacy,lymphocyte proliferation activity,and cytokines in chickens.Analyze the impact of each CpG ODN on the immune effect of chicken Newcastle disease vaccine.Results:The neutralizing antibody titer of chickens with BV-BXY-F+CpG ODN B combined immunization group was the highest at 42 days after immunization,and the immune protection rate of chickens with BV-BXY-F+CpG ODN B was 100%.sIgA antibody content,neutralizing antibody titer,IgG,IgA,IFN-γ,IL-2,IL-4,CD4^+T cells,CD8^+T cells compared with BV-BXY-F+CpG ODN P,increased by 8.44%,32.08%,13.56%,23.71%,50.20%,132.97%,39.76%,38.43%,25.99% respectively,and the difference was significant(P<0.05).Compared with the independent immunization group of chickens with BV-BXY-F increased by 13.71%,89.39%,10.41%,21.26%,159.17%,52.71%,237.84%,80.51%,75.57%.Conclusion:BV-BXY-F+CpG ODN B is the best immune group,and CpG ODN B is the best type of immune adjuvant.
作者 王长丽 黄祯雄 王胜秋 吕进 宾晓芸 杨睿睿 唐华英 WANG Chang-Li;HUANG Zhen-Xiong;WANG Sheng-Qiu;LYU Jin;BIN Xiao-Yun;YANG Rui-Rui;TANG Hua-Ying(Youjiang Medical University for Nationalitis,Baise 533000,China)
机构地区 右江民族医学院
出处 《生物技术通讯》 CAS 2020年第4期409-415,共7页 Letters in Biotechnology
基金 国家自然科学基金(31270143) 广西自然科学基金(2020GXNSFAA259034,2017JJA10377) 广西高校中青年教师基础能力提升项目(2020KY13007) 右江民族医学院2019年度校级科研课题(yy2019ky013) 右江民族医学院2018年度校级科研课题(01002018014)。
关键词 CpG ODN B型 P型 鸡新城疫重组杆状病毒疫苗 免疫佐剂 CpG ODN type B type P recombinant baculovirus vaccine against Newcastle disease in chickens immunologic adjuvant
  • 相关文献

参考文献1

二级参考文献21

  • 1Marciani D J. Vaccine adjuvant: role and mechanisms of action in vaccine immuogenicty. Drug-Discov-Today, 2003, 8 (20):934-943
  • 2Podda A, Del-Giudice G. MF59-adjuvanted vaccines:increased immunogenicity with an optimal safety profile. Expert Rev Vaccines, 2003, 2(2): 197-203
  • 3Garcon N, Heppner D G, Cohen J. Development of RTS, S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines, 2003,2(2): 231-238
  • 4Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines, 2002, 1 ( 1 ): 111-118
  • 5Bungener L, Idema J, Ter-Veer W, et al. Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res,2002,12(1-2): 155-163
  • 6Kersten G F, Crommelin D J. Liposomes and ISCOMs.Vaccine,2003, 21(9-10): 915-920
  • 7Guy B, Pascal N, Francon A, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine,2001, 19(13-14): 1794 - 1805
  • 8Pajak B, Garze V, Davies G, et al. The adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo. Vaccine,2003, 21 (9-10): 836-842
  • 9Lemere C A, Spooner E T, Leverone J F, et al. Intranasal immunotherapy for the treatment of Alzheimer' s disease:Escherichia coli LT and LT (R192G) as mucosal adjuvants.Neurobiol-Aging,2002, 23 (6): 991 - 1000
  • 10Singh A P, Puri S K, Chitnis C E. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol,2002,121(1): 21 -31

共引文献8

同被引文献28

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部